Abstract:The first 1000 days after birth are critical to the development of gut microbiome. During this period, the gut microbiota of premature infants shows reduced diversity and delayed maturation as compared to the term infants. This delayed in maturity makes preterm vulnerable to several diseases such as NEC,a inflammatory severe gastrointestinal disease in preterm infants.Studies suggest that NEC development may be linked to the overgrowth of specific pathogenic microbes or a deficiency in protective microbiota. Further studies are needed to elucidate the causal relationship between the gut microbiome and NEC and to develop targeted prevention and treatment strategies based on these findings. The role of human breast milk microbiota in shaping the gut microbiome of preterm infants may offer useful insights (Zeng et al.,2022). Therefore, finding new biomarkers in the gut microbiota is crucial for early prediction of NEC. A cohort study of preterm infants identified increased levels of Streptococcus salivarius and Rothia mucilaginosa in NEC subjects, while reduced abundance of Bifidobacterium animalis subsp. lactis and lower levels of short chain fatty acids (SCFA), acetate, propionate, and butyrate, suggesting their potential application as NEC biomarkers (Liu et al.,2022b). Some researchers have attempted to use Bifidobacterium longum BAA-2573 to intervene in colitis and have found beneficial effects linked to an increase in SCFA (Lin et al.,2023). L. paracasei BNCC345679 can also reduce colitis symptoms by restoring the diversity of the intestinal microbiota, especially increasing the abundance of beneficial bacteria such as Lactobacillus sp and Akkermansia sp (Ahmad et al.,2024). In addition to NEC, ulcerative colitis (UC) may also benefit from microbiota modulation.UC is a global public health problem, with a rising incidence, especially among children. Dysbiosis of the gut microbiota is considered the main cause of chronic intestinal inflammation. So probiotics have emerged as adjunctive therapy for UC in recenr years, aiding in microbiota restructuring, enhancing intestinal barriers, regulating immune responses and reducing inflammation. However, its safety and clinical application still need further research (Huang et al.,2023). In recent years, the gut-brain axis has played an increasingly important role in the treatment of nervous system diseases. Epilepsy is a chronic nervous system disease. Clinical studies in infants with epilepsy accompanied by diarrhea have found that Bifidobacterium may be downregulated, suggesting it could serve as a potential intestinal flora marker and aid in developing new diagnostic and treatment strategies for epilepsy (Liu et al.,2022). In addition, some researchers verified the association between intestinal flora and Hirschsprung disease (HSCR) through a public database using a two-sample Mendelian randomization method (MR). Two-sample MR is used to assess the causal relationship between exposure and outcome. Forward MR analyzes the impact of exposure on the outcome, while reverse MR examines the influence of the outcome on the exposure. In the forward MR analysis, Eggerthella was found to be associated with an increased risk of HSCR, while Peptococcus, Ruminococcus and Praprevotella were associated with a reduced risk of HSCR. Reverse MR analysis showed that HSCR is the risk factor for Eggerthella, which could provide a new strategy for HSCR treatment (Liu et al.,2024). In addition to the above clinical and preclinical studies, the special issue also emphasizes the importance of some clinical techniques, such as the high sensitivity and specificity of abdominal ultrasound in diagnosing NEC perforations, which helps to detect severely ischemic or necrotic intestinal segments earlier, thereby possibly reducing the morbidity and mortality of NEC (Chen et al.,2023).BPD is a severe chronic lung disease common in premature infants. Clinical studies have shown that children with BPD have lower intestinal microbial diversity than healthy individuals, and there are significant differences in the intestinal microbiota structure between the two groups. Children with BPD have a higher relative abundance of Proteobacteria, while Firmicutes have a lower relative abundance (Zhang et al.,2022). Therefore, gut microbial modulations of patients with BPD is also a new strategy for the treatment of BPD. There is a significant correlation between intestinal microorganisms in children and allergic rhinitis (AR), and changes in intestinal microorganisms are significantly correlated with clinical symptoms in children with AR, such as nasal symptom scores, eosinophil count, total immunoglobulin E level, etc. This indicates that the enteropulmonary axis is expected to become a new strategy for the treatment of AR (Zhang et al.,2022). The gut-lung axis is an important mechanism affecting gut and lung immunity, but few studies have examined the corr -Abstract Truncated-

Early Gut Microbiota Changes in Preterm Infants with Bronchopulmonary Dysplasia: A Pilot Case–Control Study

Risk Factors for Bronchopulmonary Dysplasia Infants with Respiratory Score Greater Than Four: a Multi-Center, Prospective, Longitudinal Cohort Study in China

Change of intestinal microbiota in mice model of bronchopulmonary dysplasia

Metabolomic Analysis Reveals the Association of Severe Bronchopulmonary Dysplasia with Gut Microbiota and Oxidative Response in Extremely Preterm Infants

Editorial: New and advanced mechanistic insights into the influences of the infant gut microbiota on human health and disease

Dynamic changes of the gut microbial colonization in preterm infants with different time points after birth

Gut Microbiota and Bronchopulmonary Dysplasia.

Role of Gut Microbiota in Neonatal Lung Injury: Implications for Bronchopulmonary Dysplasia

Association between probiotics and bronchopulmonary dysplasia in preterm infants

Antibiotics and beyond: Unraveling the dynamics of bronchopulmonary dysplasia in very preterm infants

Development of severe bronchopulmonary dysplasia is associated with alterations in fecal volatile organic compounds

Gut and Lung Microbiota in Preterm Infants: Immunological Modulation and Implication in Neonatal Outcomes

Effect of antibiotic-induced intestinal dysbacteriosis on bronchopulmonary dysplasia and related mechanisms

Clinical characteristics of bronchopulmonary dysplasia in very preterm infants

Impact of Postnatal Antibiotics and Parenteral Nutrition on the Gut Microbiota in Preterm Infants During Early Life

Changes of Postnatal Gut Microbiota in Preterm Infants Using Illumina High-Throughput Sequencing Technology

The emerging roles of microbiome and short-chain fatty acids in the pathogenesis of bronchopulmonary dysplasia

Early metabolic markers as predictors of respiratory complications in preterm infants with bronchopulmonary dysplasia

Predictive values of clinical data,molecular biomarkers, and echocardiographic measurements in preterm infants with bronchopulmonary dysplasia

Gut microbiota in preterm infants with late-onset sepsis and pneumonia: a pilot case-control study

Changes in the intestinal microbiome of the preterm baby associated with stopping non-invasive pressure support: a prospective cohort study